Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody

BACKGROUND: A small proportion of patients with advanced esophageal squamous cell carcinoma (ESCC) could benefit from immune checkpoint inhibitors; however, reliable peripheral blood biomarkers for outcomes of anti‐PD‐1 immunotherapy in ESCC have not been identified. METHODS: The data of 43 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xi, Zhang, Bo, Chen, Xuelian, Mo, Hongnan, Wu, Dawei, Lan, Bo, Li, Qun, Xu, Binghe, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558460/
https://www.ncbi.nlm.nih.gov/pubmed/31017739
http://dx.doi.org/10.1111/1759-7714.13083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558460/
https://www.ncbi.nlm.nih.gov/pubmed/31017739
http://dx.doi.org/10.1111/1759-7714.13083

Ejemplares similares